ИИ ежедневно анализирует ведущие российские и международные источники, отбирает значимые исследования, рекомендации и новости и представляет их врачу в кратком структурированном формате.
Конференции, вебинары и симпозиумы по онкологии от ведущих организаций мира.
Организатор: ESTRO
Организатор: ESTRO
Организатор: MASCC Supportive Care Events
Организатор: ESTRO
Организатор: Российское общество онкоурологов
Вебинар по опухолям центральной нервной системы: глиобластома, метастазы в ЦНС, менингиомы.
Организатор: RUSSCO
Организатор: ESMO Meeting Calendar
Организатор: EBMT Educational Events & Meetings
Организатор: НМИЦ радиологии Минздрава России
Downloadable pocket guide to assist oncology nurses in quickly identifying and assessing the severity of ADC-related adverse events associated with sacituzumab govitecan and datopotamab deruxtecan in the management of patients with HR-positive, HER2-negative metastatic breast cancer, including the evolving nursing role, factors that nurses should consider to deliver safe and high-quality care, measures to use to optimize the early recognition of adverse events, and institute early intervention to improve adherence while utilizing shared treatment decision-making approaches to optimize treatment outcomes.
Организатор: Decera Clinical
In this podcast, experts review practice-informing data presented at the ASCO 2026 annual conference that may reshape treatment decisions in metastatic breast cancer. The discussion examines ctDNA-guided treatment adaptation for emergent ESR1 mutations in HR-positive/HER2-negative disease, emerging endocrine-based precision strategies targeting ER and PI3K/AKT signaling, and first-line TROP2-directed antibody-drug conjugates in metastatic triple-negative breast cancer. The experts place the SERENA-6, ELEVATE, PIKALO-1, ASCENT-04, ASCENT-03, and TROPION-Breast02 findings in clinical context and how the results, including biomarker testing, immunotherapy eligibility, sequencing, safety, and the maturity of the evidence are influencing their clinical practice.
Организатор: Decera Clinical
Организатор: College of American Pathologists (CAP) Events
Esaminare le evidenze fondamentali degli studi di fase III a sostegno dei recenti aggiornamenti delle indicazioni approvate per gli anticorpi farmaco-coniugati (ADC) anti-TROP2 nel carcinoma mammario metastatico HR-positivo/HER2-negativo e triplo-negativo, con particolare attenzione al ruolo dei nuovi dati di efficacia e sicurezza nella scelta del trattamento. Approfondire i criteri adottati dagli esperti per la scelta della terapia in prima linea e nelle linee successive, tenendo conto della possibilità di offire un trattamento contenete immunoterapia e del profilo degli eventi avversi degli ADC diretti contro TROP2 disponibili. Infine, approfondire come monitorare i potenziali eventi avversi che possono limitare la prosecuzione della terapia e come prevenirli e trattarli, integrando allo stesso tempo della terapia, terapiae di supporto finalizzate al miglioramento della qualità di vita.
Организатор: Decera Clinical
Организатор: College of American Pathologists (CAP) Events
Организатор: Ассоциация специалистов по проблемам меланомы
Организатор: College of American Pathologists (CAP) Events
Организатор: College of American Pathologists (CAP) Events
Организатор: MASCC Supportive Care Events
Организатор: ESTRO
Erkunden Sie wegweisende Phase-III-Evidenz, die zu den kürzlichen aktualisierten Arzneimittel-Zulassungserweiterung für TROP2-ADCs bei metastasiertem HR-positivem/HER2-negativem und dreifach negativem Mammakarzinom geführt hat. Ein Schwerpunkt sind die neuen Wirksamkeits- und Sicherheitsdaten, die Behandlungsauswahl beeinflussen. Erfahren Sie mehr über die Abwägungen von Expertinnen und Experten bei der Auswahl einer Therapie in der Erstlinien- und Folgelinienbehandlung, basierend auf der Eignung für eine Immuntherapie und dem Nebenwirkungsprofil der verfügbaren TROP2-gerichteten Antikörper-Wirkstoff-Konjugate (ADCs). Lernen Sie schließlich, wie Sie potenzielle unerwünschte Ereignisse, die die Therapiedauer beeinträchtigen könnten, antizipieren und wie Sie diese mit Supportivtherapien abmildern können.
Организатор: Decera Clinical
Организатор: EAU
Организатор: Decera Clinical
In this commentary, experts review the evolving role of TROP-2–directed antibody–drug conjugates (ADCs) in metastatic triple-negative breast cancer, with emphasis on first-line treatment selection, sequencing after progression, and management of agent-specific toxicities. The discussion examines phase III data from KEYNOTE-355, ASCENT-04/KEYNOTE-D19, ASCENT-03, TROPION-Breast02, and ASCENT, including progression-free survival, overall survival, response rates, and PFS2, while highlighting important differences in trial design that limit cross-trial comparisons. The experts also address how PD-L1 and germline BRCA1/2 status, prior therapy, disease characteristics, toxicity profiles, supportive care needs, and treatment schedules inform ADC selection and sequencing. Practical considerations related to managing neutropenia, diarrhea, stomatitis, ocular toxicity, and ILD/pneumonitis are reviewed alongside strategies to support timely treatment, toxicity monitoring, biomarker testing, and equitable access to ADC therapy and clinical trials.
Организатор: Decera Clinical
Организатор: EORTC
Организатор: Decera Clinical
Despite the evolving evidence supporting earlier use of BCMA-directed CAR T-cell therapy in multiple myeloma, practical gaps remain in patient selection, referral timing, bridging therapy, treatment sequencing, and shared-care coordination. This interactive case challenge follows an older, fit patient with high-risk multiple myeloma who experiences an early relapse and is being considered for BCMA-directed CAR T-cell therapy. Through expert-guided branching decisions, you will evaluate CAR T-cell eligibility, select an appropriate bridging strategy, consider sequencing with bispecific antibodies and other therapies, and recognize and manage delayed CAR T-cell therapy–associated neurotoxicity.
Организатор: Decera Clinical
Организатор: EAU
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Эксперты в области онкологии, радиологии и ядерной медицины — о внедрении высокотехнологичной помощи в стандарты лечения. Клиника Медскан | Hadassah, Сколково.
Организатор: Клиника Hadassah при поддержке Фонда ММК и GE HealthCare
Организатор: ESMO Meeting Calendar
As oral targeted therapies for HR-positive/HER2-negative breast cancer expand, nurses need practical guidance to identify and manage overlapping adverse events, support treatment adherence, and help patients achieve the full benefit of therapy. These downloadable slides summarize indications, dosing, and administration of approved oral targeted agents along with nursing-focused clinical pearls related to AE monitoring and management.
Организатор: Decera Clinical
This expert commentary examines the evolving role of GPRC5D-directed therapy in multiple myeloma, including the biologic rationale for targeting GPRC5D and clinical evidence supporting talquetamab across treatment settings. It also explores emerging approaches to sequencing and combining GPRC5D- and BCMA-directed therapies, ongoing studies evaluating earlier-line use such as the phase III MonumenTAL-3 trial, and practical strategies for recognizing and managing unique toxicities associated with GPRC5D-targeted treatment like skin, nail, and taste changes.
Организатор: Decera Clinical
In relapsed/refractory multiple myeloma, prior therapy can affect subsequent treatment efficacy, highlighting the importance of thoughtful sequencing and consideration of alternative targets. Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates, bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.
Организатор: Decera Clinical
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
New approvals in the neoadjuvant and adjuvant settings of HER2-positive early breast cancer are increasing the complexity of selecting optimal treatment. This patient case challenges you to navigate the treatment options based on initial disease burden, treatment tolerability, HER2 reassessment, response to neoadjuvant treatment, and currently available trial evidence.
Организатор: Decera Clinical
Discover how to recognize, monitor, and escalate delayed and long-term toxicities after CAR T-cell therapy in this oncology nursing pocket guide designed to turn current guidelines and expert recommendations into concise clinical workflows to support risk assessment, patient and caregiver education, symptom triage, and timely communication with the cellular therapy center. Topics covered include cytopenias, infections, hypogammaglobulinemia, vaccination counseling, antimicrobial prophylaxis, and more.
Организатор: Decera Clinical
Downloadable slides on the evolving management of immune thrombocytopenia (ITP), including disease pathophysiology, treatment-related burden, and current guideline-based approaches across lines of therapy. The slides review evidence for established options such as corticosteroids, rituximab, thrombopoietin receptor agonists (TPO-RAs), fostamatinib, and splenectomy, as well as clinical trial data for newer and emerging immune-targeted therapies, including rilzabrutinib, ianalumab, efgartigimod, and mezagitamab. Key studies reviewed include LUNA 3, VAYHIT1/2/3, and ADVANCE IV, with attention to platelet response, treatment failure, fatigue, bleeding, safety, and sustained response off treatment. The slides also emphasize durability-focused treatment goals, TPO-RA tapering, and shared decision-making to help individualize therapy according to disease control, treatment burden, adverse effects, and patient preferences.
Организатор: Decera Clinical
Организатор: ESTRO
Ежегодное заседание Американского общества радиационной онкологии. Лучевая терапия и радиационная онкология.
Организатор: ASTRO
Организатор: ESGO Meeting Calendar
Neoadjuvant therapy has evolved into a platform for prognosis, treatment selection, and therapeutic innovation in HER2-positive breast cancer. These slides review the evidence for removing anthracyclines from routine neoadjuvant treatment, eliminating carboplatin, and potentially replacing chemotherapy with targeted treatments. The current landscape of personalized neo/adjuvant treatment selection relies on factors including initial disease burden, previous treatments, and residual disease burden.
Организатор: Decera Clinical
Treatment of early-stage non-small-cell lung cancer (NSCLC) continues to evolve with biomarker-guided treatment selection and expanding neoadjuvant, adjuvant, and perioperative immunotherapy options. This text module examines the role of comprehensive biomarker testing, practical challenges that may delay testing and treatment decisions, and evidence from pivotal phase III trials to guide the selection and sequencing of immunotherapy for patients with resectable NSCLC.
Организатор: Decera Clinical
This toolkit empowers patients with multiple myeloma and their care partners to participate in shared decision-making throughout the disease course by understanding treatment options and sequencing, monitoring response, recognizing and reporting side effects, and accessing supportive care, financial assistance, and clinical trials. Download now to review important information about treatment for multiple myeloma, including key questions to ask your care team.
Организатор: Decera Clinical
Организатор: EAU
Организатор: Onco-Academy
Организатор: EAU
Организатор: Decera Clinical
This slideset with an accompanying video module examines the rapidly evolving treatment landscape for HER2-positive metastatic breast cancer, focusing on evidence from key clinical trials that are reshaping first-line therapy, maintenance strategies, and treatment sequencing. Explore how emerging data on HER2-directed therapies inform individualized treatment decisions, including when to incorporate T-DXd, tucatinib, and other targeted approaches, how to navigate limited evidence following T-DXd progression, and how to integrate systemic and local therapies for patients with CNS metastases.
Организатор: Decera Clinical
In this podcast, experts discuss the evolving role of PARP inhibitors in metastatic prostate cancer, with a focus on the biologic rationale for PARP inhibition in tumors with HRR alterations, the importance of germline and somatic genomic testing, and the clinical evidence supporting PARP inhibitor monotherapy and combinations with ARPI. The discussion highlights data from trials including AMPLITUDE and TALAPRO-3, considers how specific HRR alterations may influence treatment selection across metastatic disease settings, and reviews practical strategies for monitoring and managing adverse events such as anemia and nausea.
Организатор: Decera Clinical
Neoadjuvant therapy has evolved into a platform for prognosis, treatment selection, and therapeutic innovation in HER2-positive breast cancer. This video module reviews the evidence for removing anthracyclines from routine neoadjuvant treatment, eliminating carboplatin, and potentially replacing chemotherapy with targeted treatments. The current landscape of personalized neo/adjuvant treatment selection relies on factors including initial disease burden, previous treatments, and residual disease burden.
Организатор: Decera Clinical
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Вебинар по лечению метастатического рака молочной железы: новые данные и клинические решения.
Организатор: RUSSCO
Организатор: НМИЦ онкологии им. Н.Н. Петрова
Организатор: ASTCT Meetings
Организатор: Onco-Academy
Организатор: SIOP Community Calendar
Организатор: Onco-Academy
The delivery and management of immunotherapy for non-small-cell lung cancer continue to evolve with the approval of subcutaneous immune checkpoint inhibitor formulations and increasing emphasis on proactive toxicity management. This text module explores the efficacy, safety, administration, resource use, and potential effects of subcutaneous immunotherapy on the patient experience. It also provides practical guidance for recognizing and managing immune-related adverse events and counseling patients and caregivers throughout treatment.
Организатор: Decera Clinical
This expert commentary discusses insights gained from our educational program addressing low-dose CT screening for the early detection of lung cancer. Despite the substantial burden of lung cancer in the United States, use of low-dose CT screening among eligible individuals remains low. Experts examine current eligibility criteria, strategies to improve screening among underserved populations, and emerging approaches to lung cancer risk assessment and detection. They also consider patients who do not clearly meet current USPSTF screening criteria but may be at higher risk for lung cancer, including how additional risk factors may inform decisions about low-dose CT screening.
Организатор: Decera Clinical
This video module examines the rapidly evolving treatment landscape for HER2-positive metastatic breast cancer, focusing on evidence from key clinical trials that are reshaping first-line therapy, maintenance strategies, and treatment sequencing. Explore how emerging data on HER2-directed therapies inform individualized treatment decisions, including when to incorporate T-DXd, tucatinib, and other targeted approaches, how to navigate limited evidence following T-DXd progression, and how to integrate systemic and local therapies for patients with CNS metastases.
Организатор: Decera Clinical
Организатор: MASCC Supportive Care Events
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: Onco-Academy
Организатор: Decera Clinical
In this on-demand webcast, experts review the evolving role of CAR T-cell therapy across B-cell malignancies, including the underlying principles of autologous CAR T-cell treatment, currently approved products, and clinical trial data supporting their use in large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma. The faculty also discuss practical considerations for integrating CAR T-cell therapy into clinical care, including timely referral to authorized treatment centers, patient selection, bridging therapy, coordination between community and academic teams, and inpatient vs outpatient treatment approaches. In addition, the webcast addresses recognition and management of acute and delayed toxicities, including cytokine release syndrome, ICANS, cytopenias, hypogammaglobulinemia, and infection risk, as well as prophylaxis and long-term monitoring strategies. Emerging approaches, including dual-targeting CAR T-cell constructs and rapid-manufacturing strategies, are also highlighted, underscoring how current evidence and evolving best practices can inform treatment selection, referral, toxicity management, and longitudinal care.
Организатор: Decera Clinical
Организатор: AACR Meetings & Workshops
Вебинар по иммунотерапии меланомы кожи: ингибиторы контрольных точек, комбинированные режимы.
Организатор: RUSSCO
Организатор: EBMT Educational Events & Meetings
This activity reviews evolving evidence and clinical decision-making for adjuvant therapy in patients with HER2-positive early breast cancer (EBC), with a focus on tailoring treatment according to pathologic response, baseline stage, residual disease burden, and recurrence risk. Key data include long-term outcomes from APHINITY and KATHERINE, emerging evidence from DESTINY-Breast05 comparing adjuvant trastuzumab deruxtecan (T-DXd) with trastuzumab emtansine (T-DM1) in patients with high-risk residual disease, and considerations related to CNS recurrence, treatment toxicity, and reassessment of HER2 status after neoadjuvant therapy. The activity also addresses extended adjuvant neratinib, endocrine therapy selection in HR-positive/HER2-positive disease, and the evolving choice between neoadjuvant and adjuvant T-DXd, highlighting how these data may inform individualized treatment selection and risk-adapted management in clinical practice.
Организатор: Decera Clinical
Организатор: College of American Pathologists (CAP) Events
Организатор: SIOP Community Calendar
Although there are no approved drugs targeting cadherin-6 (CDH6) yet, there are multiple agents in clinical trials. This activity will present evidence explaining why the biology of CDH6 suits the development of therapeutic antibody–drug conjugates (ADCs) directed towards it. Learners will see how CDH6 expression patterns in ovarian cancer are key to this emerging drug class. Other points in the activity will explain the biologic role of cadherins in ovarian tumors, the design principles of ADCs, and preclinical scientific data from CDX and PDX ovarian cancer models supporting the concept of CHD6-ADC.
Организатор: Decera Clinical
Explore current and emerging evidence for TROP2-directed ADCs in triple-negative breast cancer, including first-line treatment for patients who are not candidates for immunotherapy and later-line sequencing. Review individualized treatment selection and multidisciplinary prevention and management of ADC-associated toxicities.
Организатор: Decera Clinical
This expert commentary examines emerging evidence for CELMoDs, particularly golcadomide, in lymphoma and considers how these investigational agents may be integrated into community oncology practice. It also reviews efficacy and safety data across lymphoma settings, including combinations with rituximab, chemoimmunotherapy, and bispecific antibodies, while considering practical issues such as adverse event management, differentiation from lenalidomide, treatment accessibility, and academic–community collaboration. Finally, the experts highlight implementation strategies that may help healthcare professionals prepare for CELMoDs while emphasizing the need for ongoing randomized trial data to define their role in routine care.
Организатор: Decera Clinical
Explore current evidence and emerging strategies for antibody–drug conjugates in patients with platinum-resistant ovarian cancer, including biomarker-guided use of FRα-directed and HER2-directed therapies and the evolving roles of investigational targets. Examine how biomarker results, prior treatment, rate of disease progression, comorbidities, baseline toxicity risk, patient goals, along with multidisciplinary workflows for treatment readiness and escalation of care.
Организатор: Decera Clinical
These slides and accompanying video module review evolving evidence and clinical decision-making for adjuvant therapy in patients with HER2-positive early breast cancer (EBC), with a focus on tailoring treatment according to pathologic response, baseline stage, residual disease burden, and recurrence risk. Key data include long-term outcomes from APHINITY and KATHERINE, emerging evidence from DESTINY-Breast05 comparing adjuvant trastuzumab deruxtecan (T-DXd) with trastuzumab emtansine (T-DM1) in patients with high-risk residual disease, and considerations related to CNS recurrence, treatment toxicity, and reassessment of HER2 status after neoadjuvant therapy. The slides also address extended adjuvant neratinib, endocrine therapy selection in HR-positive/HER2-positive disease, and the evolving choice between neoadjuvant and adjuvant T-DXd, highlighting how these data may inform individualized treatment selection and risk-adapted management in clinical practice.
Организатор: Decera Clinical
In this on-demand webcast, experts review the clinical rationale for targeting TROP2 in metastatic triple-negative breast cancer (mTNBC) and the evolving role of TROP2-directed antibody–drug conjugates (ADCs), with emphasis on first-line treatment of patients who are not candidates for immunotherapy. The faculty discuss efficacy and safety data from key randomized trials, including ASCENT-03 and TROPION-Breast02, and consider how differences in trial populations, treatment-free interval, prior therapy, comorbidities, and patient preferences may inform selection between sacituzumab govitecan and datopotamab deruxtecan. The faculty also address prevention and management of treatment-related toxicities, including neutropenia, diarrhea, stomatitis, ocular surface events, and interstitial lung disease, as well as practical strategies for supportive care and multidisciplinary monitoring. Finally, the experts explore sequencing considerations after TROP2-directed ADC therapy, the potential impact of ADC resistance mechanisms, ongoing phase III studies in early and advanced TNBC, and emerging data in patients with active brain metastases, highlighting factors that may influence individualized treatment planning across the disease course.
Организатор: Decera Clinical
Организатор: College of American Pathologists (CAP) Events
Организатор: College of American Pathologists (CAP) Events
Межрегиональная междисциплинарная научно-практическая онкологическая конференция: гериатрическая онкология, кардиоонкология, коморбидный пациент, ИИ в онкологии. Экзамен RUSSCO, мастер-класс «Живая хирургия».
Организатор: Минздрав Нижегородской области, Ассоциация онкологов России, НИИКО «НОКОД», ПИМУ
Организатор: OncoSib — Ассоциация онкологических организаций Сибири и ДВ
Организатор: ESMO Meeting Calendar
Listen to expert faculty discuss the evolving role of quadruplet therapy in newly diagnosed multiple myeloma, with an emphasis on treatment selection across transplant-eligible and transplant-ineligible populations, the incorporation of proteasome inhibitors, and the tailoring of treatment intensity. The experts also examine unresolved questions regarding the optimal use of bortezomib, the role of autologous stem cell transplantation in the quadruplet era, and the use of MRD status to inform treatment decisions. Maintenance strategies with lenalidomide alone or in combination with anti-CD38 therapy are also discussed.
Организатор: Decera Clinical
Providing equitable, patient-centered care in myelofibrosis requires addressing the complex interplay of patient, disease, treatment, and health system factors that influence outcomes. This slideset explores practical strategies to advance equitable, patient-centered myelofibrosis care by addressing barriers to treatment access, incorporating symptom and quality-of-life assessment, strengthening shared decision-making and patient–provider communication, and leveraging multidisciplinary collaboration to support individualized treatment goals and improve patient experience.
Организатор: Decera Clinical
In this commentary, expert faculty discuss the evolving role of quadruplet therapy in newly diagnosed multiple myeloma, with emphasis on treatment selection across transplant-eligible and transplant-ineligible populations, incorporation of anti-CD38 antibodies and proteasome inhibitors, and tailoring treatment intensity according to disease risk, fitness, and response. The faculty examine phase III and other clinical data informing contemporary frontline treatment and address unresolved questions regarding the optimal use and duration of bortezomib, the role of autologous stem cell transplantation in the quadruplet era, and the use of MRD status to inform treatment decisions. Maintenance strategies with lenalidomide alone or in combination with anti-CD38 therapy are also discussed.
Организатор: Decera Clinical
Организатор: MASCC Supportive Care Events
Providing equitable, patient-centered care in myelofibrosis requires addressing the complex interplay of patient, disease, treatment, and health system factors that influence outcomes. In this text module, expert faculty explore practical strategies to advance equitable, patient-centered myelofibrosis care by addressing barriers to treatment access, incorporating symptom and quality-of-life assessment, strengthening shared decision-making and patient–provider communication, and leveraging multidisciplinary collaboration to support individualized treatment goals and improve patient experience.
Организатор: Decera Clinical
In relapsed/refractory multiple myeloma, prior therapy can affect subsequent treatment efficacy, highlighting the importance of thoughtful sequencing and consideration of alternative targets. In this commentary, expert faculty discuss sequencing of antibody–drug conjugates, bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.
Организатор: Decera Clinical
Организатор: EAU
Организатор: College of American Pathologists (CAP) Events
Организатор: Decera Clinical
Организатор: НМИЦ онкологии им. Н.Н. Петрова
The care of patients diagnosed with high-risk smoldering multiple myeloma (MM) or newly diagnosed active MM continues to evolve with the rapid release of new clinical evidence. This module features an expert’s evidence-based perspectives on the need for accurate risk stratification, evidence for early intervention, and how to decide between treatment and observation in an individualized manner for patients with high-risk smoldering MM, as well as the optimal approaches for the selection of frontline therapy for patients who are newly diagnosed with active MM requiring treatment. The module also includes a synthesized review of the evolving treatment landscape, recommended guidelines, and ongoing clinical trials for patients with high-risk smoldering MM and those with newly diagnosed active MM.
Организатор: Decera Clinical
In this on-demand webcast, an expert reviews the evolving role of HER2-targeted therapies in gastroesophageal adenocarcinoma and biliary tract cancer, emphasizing the importance of biomarker testing, treatment selection, and proactive toxicity management. Clinical trial evidence supporting established and emerging HER2-directed treatment strategies, including trastuzumab-based regimens, zanidatamab, and trastuzumab deruxtecan, is discussed, along with their efficacy, safety profiles, and implications for treatment sequencing. Key considerations include HER2 testing and reassessment at disease progression, recognition and management of treatment-related adverse events such as infusion-related reactions, diarrhea, and interstitial lung disease/pneumonitis, and strategies for patient education and symptom triage. The faculty also highlights the role of oncology nurses in multidisciplinary care coordination, shared decision-making, and early intervention to support treatment tolerability and optimize patient outcomes.
Организатор: Decera Clinical
In this podcast episode, experts discuss the evolving treatment landscape of R/R mantle cell lymphoma as the use of covalent BTK inhibitors further expands into the first-line setting. The discussion highlights the similarities and differences between small molecules pirtobrutinib and sonrotoclax including patient selection, step-up dosing requirements, TLS monitoring, efficacy post covalent BTKi, sequencing, and the feasibility of implementing treatment in community practices. They also examine the dosing, efficacy, and safety of CAR T-cell therapy and bispecific antibodies, establishing their current and possible future roles in R/R MCL.
Организатор: Decera Clinical
Организатор: Onco-Academy
Организатор: Onco-Academy
Downloadable slides featuring evidence for the need for accurate risk stratification, evidence for early intervention, and how to decide between treatment and observation in an individualized manner for patients with high-risk smoldering MM, as well as the optimal approaches for the selection of frontline therapy for patients who are newly diagnosed with active MM requiring treatment. Slides also include a synthesized version of the evolving treatment landscape, recommended guidelines, and ongoing clinical trials for patients with high-risk smoldering MM and those with newly diagnosed active MM.
Организатор: Decera Clinical
Recent phase III trial data have expanded first-line treatment options for patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who are not candidates for immune checkpoint inhibitor therapy. In this activity, learners will examine the clinical rationale for targeting TROP2, key differences among TROP2-directed antibody–drug conjugates, and efficacy and safety findings from the ASCENT-03 and TROPION-Breast02 phase III trials. Learners will also explore how PD-L1 status, disease burden, comorbidities, toxicity profiles, and patient preferences inform individualized treatment selection, safety monitoring, and integration of TROP2-directed therapies into the frontline setting.
Организатор: Decera Clinical
Downloadable slides on the evolving role of TROP-2–directed antibody–drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC), including recent clinical trial evidence, biomarker development, treatment sequencing, and adverse event management. The slides review differences in the mechanisms of action and safety profiles of datopotamab deruxtecan, sacituzumab govitecan, and sacituzumab tirumotecan, along with efficacy and safety findings from pivotal and emerging trials, including TROPION-Lung01/02/05, EVOKE-01/02, and OptiTROP-Lung01, 03, 04, and 05. Data are examined across patient subgroups defined by histology, EGFR mutation status, PD-L1 expression, and prior treatment, with consideration of approved indications, investigational combinations, and emerging TROP-2 biomarker approaches. The slides also address practical strategies for preventing, monitoring, and managing ADC-associated toxicities, including stomatitis, ocular adverse events, neutropenia, diarrhea, and interstitial lung disease/pneumonitis, providing clinical context for individualized treatment selection, sequencing, and supportive care in advanced NSCLC.
Организатор: Decera Clinical
Review these results from a multisite quality improvement (QI) initiative combining accredited education and QI coaching across 3 cancer centers. The initiative demonstrated improvements in the timeliness of biomarker testing and targeted therapy initiation for patients with advanced solid tumors, alongside gains in healthcare professional knowledge and competency related to precision oncology.
Организатор: Decera Clinical
Организатор: EBMT Educational Events & Meetings
Организатор: ASH Annual Meeting
Организатор: Onco-Academy
Организатор: SIOP Community Calendar
In this commentary, experts discuss clinical evidence and practical considerations for optimizing nursing care of patients with relapsed/refractory multiple myeloma receiving bispecific antibody therapy. The commentary highlights efficacy findings from the MajesTEC-3 and MajesTEC-1 trials and examines the recognition and management of treatment-related adverse events, including CRS, ICANS, and infections. Strategies for infection prevention, including IVIG prophylaxis, and supportive care approaches for managing talquetamab-associated toxicities are addressed. The experts also emphasize patient and caregiver education, early symptom recognition, and coordination between academic and community oncology settings to support safe treatment administration, timely intervention, and preservation of patients' quality of life.
Организатор: Decera Clinical
Although there are no approved drugs targeting cadherin-6 (CDH6) yet, multiple agents are in clinical trials. This activity focuses on the integration, utility, and management of CDH6-directed antibody–drug conjugates (ADCs) for patients with high-grade serous ovarian cancer. Topics covered include CDH6 expression in ovarian cancer, where potential treatment sequencing can accommodate CDH6 ADCs based on available evidence, what adverse events are of greatest potential concern with CDH6-directed ADCs, and how HCPs can manage these associated adverse events.
Организатор: Decera Clinical
In this text-based module, an expert reviews the progressive course of myelofibrosis and key considerations for individualized management, including treatment goals, assessment of spleen volume and symptom burden, use and monitoring of JAK inhibitors, and the role of hematopoietic stem cell transplantation. The module also addresses treatment-related toxicities, multidisciplinary care, and the importance of aligning therapy with disease characteristics, patient priorities, and evolving clinical needs, while highlighting clinical trial participation as an important avenue for expanding future treatment options.
Организатор: Decera Clinical
In these slides, the progressive course of myelofibrosis and key considerations for individualized management, including treatment goals, assessment of spleen volume and symptom burden, use and monitoring of JAK inhibitors, and the role of hematopoietic stem cell transplantation is reviewed. The module also addresses treatment-related toxicities, multidisciplinary care, and the importance of aligning therapy with disease characteristics, patient priorities, and evolving clinical needs, while highlighting clinical trial participation as an important avenue for expanding future treatment options.
Организатор: Decera Clinical
Организатор: College of American Pathologists (CAP) Events
Организатор: Decera Clinical
Later-line TROP2 ADC sequencing in immunotherapy-ineligible metastatic triple-negative breast cancer requires consideration of prior systemic therapy, biomarker status, and potential cross-resistance between ADCs. In this activity, learners will examine phase III evidence for sacituzumab govitecan, emerging data for investigational sacituzumab tirumotecan, and biomarker-informed alternatives after disease progression. Learners will also explore how prior ADC exposure, HER2 expression, germline BRCA1/2 status, rate of disease progression, organ function, residual toxicities from previous therapy, and clinical trial availability may help inform individualized treatment sequencing.
Организатор: Decera Clinical
The care of patients with extensive-stage (ES) small-cell lung cancer (SCLC) continues to evolve with the continuous release of new clinical evidence. Watch this video to learn more about the importance of lung cancer screening, why ES-SCLC remains a setting in need of novel treatment options and strategies, an overview of the currently approved treatments for patients with this disease, the evolving targeted therapy landscape, biology and rationale for investigating therapies targeting B7-H3, overview of clinical evidence with the use of investigational B7-H3–directed antibody–drug conjugates such as ifinatamab deruxtecan, risvutatug rezetecan, tambotatug pelitecan and elfetabart drozuntecan, and key ongoing phase III trials of B7-H3–directed therapies.
Организатор: Decera Clinical
Downloadable slides on the clinical application and safety management of CD19- and BCMA-directed CAR T-cell therapies in hematologic malignancies, with a focus on recognizing and managing acute, delayed, and long-term toxicities in community and shared-care settings. The slides review pivotal clinical trial data supporting approved CAR T-cell therapies for acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma, along with evidence-based strategies for identifying and managing cytokine release syndrome, immune effector cell–associated neurotoxicity syndrome, prolonged cytopenias, infections, hypogammaglobulinemia, and delayed neurologic complications. Practical guidance on toxicity monitoring, infection prevention, vaccination, supportive care, patient and caregiver education, and coordination between cellular therapy centers and community oncology teams supports timely intervention and continuity of care following CAR T-cell therapy.
Организатор: Decera Clinical
Downloadable slides to learn more about why B7-H3 is a clinically relevant target in ES-SCLC, and gain more insight into the biology and promising investigational agents such as ifinatamab deruxtecan (I-DXd) targeting B7-H3 in ES-SCLC.
Организатор: Decera Clinical
Организатор: EAU
Организатор: Decera Clinical
The treatment landscape for high-risk HR-positive/HER2-negative early breast cancer continues to evolve, with emerging evidence and adjuvant CDK4/6 inhibitors creating new opportunities to reduce recurrence risk and improve long-term outcomes. This expert commentary explores how healthcare professionals can translate findings from pivotal clinical trials into individualized, guideline-concordant treatment decisions while navigating differences in patient eligibility, efficacy, and safety profiles.
Организатор: Decera Clinical
In this second of 3 video modules, an expert reviews emerging clinical evidence on CDH6-directed ADCs for the treatment of ovarian cancer, with a focus on platinum-resistant disease. The faculty examines CDH6 expression and its relationship to FRα expression, along with early-phase efficacy and safety data for investigational agents, including CUSP06 and raludotatug deruxtecan. Findings from the CUSP06-1001 and REJOICE-Ovarian01 trials, including objective response rates, response durability, activity following prior ADC treatment, dose optimization, and adverse event profiles, are highlighted. Clinical outcomes are also compared with those of other ADCs evaluated in ovarian cancer, providing context for assessing the potential role of CDH6-directed therapies and interpreting emerging evidence that may inform future treatment selection and sequencing.
Организатор: Decera Clinical
Организатор: European School of Oncology (ESO)
Организатор: College of American Pathologists (CAP) Events